References
- Steinberg HO, Basel B, Ginger H, et al. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation. 1997;96(10):3287–3293. doi:https://doi.org/10.1161/01.CIR.96.10.3287.
- Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117(1):195–205. doi:https://doi.org/10.1172/JCI29950.
- Maik D, Megens RTA, Marc vZ, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010;122(18):1837–1845. doi:https://doi.org/10.1161/CIRCULATIONAHA.110.961714.
- Yvonne D, Oliver S, Maik D, et al. Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(7):1613–1623. doi:https://doi.org/10.1161/ATVBAHA.111.236539.
- Rothe G, Gabriel H, Kovacs E, et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16(12):1437–1447. doi:https://doi.org/10.1161/01.atv.16.12.1437.
- Proto JD, Doran AC, Subramanian M, et al. Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest. 2018;128(6):2370–2375. doi:https://doi.org/10.1172/JCI97785.
- Mailer RKW, Gisterå A, Polyzos KA, et al. Hypercholesterolemia enhances T cell receptor signaling and increases the regulatory T cell population. Sci Rep. 2017;7(1):15655. doi:https://doi.org/10.1038/s41598-017-15546-8.
- Collado A, Marques P, Domingo E, et al. Novel immune features of the systemic inflammation associated with primary hypercholesterolemia: changes in cytokine/chemokine profile, increased platelet and leukocyte activation. J Clin Med. 2018;8(1):18. doi:https://doi.org/10.3390/jcm8010018.
- Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95(5):1119–1121. doi:https://doi.org/10.1161/01.cir.95.5.1119.
- Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis. 1997;20(2):307–315. doi:https://doi.org/10.1023/A:1005377310872.
- Xiaokun Z, Jing D, Remick DG, Xian W. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res. 2003;93(4):311–320. doi:https://doi.org/10.1161/01.RES.0000087642.01082.E4.
- Zhang Q, Zeng X, Guo J, Wang X. Oxidant stress mechanism of homocysteine potentiating Con A-induced proliferation in murine splenic T lymphocytes. Cardiovasc Res. 2002;53(4):1035–1042. doi:https://doi.org/10.1016/S0008-6363(01)00541-7.
- Ma K, Lv S, Liu B, et al. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(–/–) mice. Cardiovasc Res. 2013;97(2):349–359. doi:https://doi.org/10.1093/cvr/cvs330.
- Joshi MB, Baipadithaya G, Balakrishnan A, et al. Elevated homocysteine levels in type 2 diabetes induce constitutive neutrophil extracellular traps. Sci Rep. 2016;6:36362. doi:https://doi.org/10.1038/srep36362.
- Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29(5):543–548. doi:https://doi.org/10.1016/j.cjca.2012.06.009.
- Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399–1402. doi:https://doi.org/10.1038/82219.
- Bu D, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22(3):165–170. doi:https://doi.org/10.1097/MOL.0b013e3283453e41.
- Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012;223(1):78–85. doi:https://doi.org/10.1016/j.atherosclerosis.2012.01.031.
- Lucia M, Duchosal MA, Martine K, et al. Endogenous angiotensin ii induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE−/− mice. Hypertension. 2004;44(3):277–282. doi:https://doi.org/10.1161/01.HYP.0000140269.55873.7b.
- Platten M, Youssef S, Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA. 2009;106(35):14948–14953. doi:https://doi.org/10.1073/pnas.0903958106.
- Li S, Wu Y, Yu G, et al. Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials. PLoS One. 2014;9(3):e90217. doi:https://doi.org/10.1371/journal.pone.0090217.
- van Dijk SC, Enneman AW, Swart KMA, et al. Effect of vitamin B12 and folic acid supplementation on biomarkers of endothelial function and inflammation among elderly individuals with hyperhomocysteinemia. Vasc Med. 2016;21(2):91–98. doi:https://doi.org/10.1177/1358863X15622281.
- Christen WG, Cook NR, Van Denburgh M, et al. Effect of combined treatment with folic acid, vitamin b6, and vitamin b12 on plasma biomarkers of inflammation and endothelial dysfunction in women. J Am Heart Assoc. 2018;7(11):2–3. doi:https://doi.org/10.1161/JAHA.117.008517.
- Yi X, Zhou Y, Jiang D, et al. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: a meta-analysis of randomized controlled trials. Exp Ther Med. 2014;7(5):1100–1110. doi:https://doi.org/10.3892/etm.2014.1553.
- Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7(10):803–815. doi:https://doi.org/10.1038/nri2171.
- Opitz B, Eitel J, Meixenberger K, Suttorp N. Role of Toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost. 2009;102(6):1103–1109. doi:https://doi.org/10.1160/TH09-05-0323.
- Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26(6):673–685. doi:https://doi.org/10.1016/j.cytogfr.2015.04.003.
- Akhtar S, Hartmann P, Karshovska E, et al. Endothelial hypoxia-inducible factor-1α promotes atherosclerosis and monocyte recruitment by upregulating microRNA-19a. Hypertension. 2015;66(6):1220–1226. doi:https://doi.org/10.1161/HYPERTENSIONAHA.115.05886.
- Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–689. doi:https://doi.org/10.1038/nri2156.
- Carman CV, Martinelli R. T-lymphocyte-endothelial interactions: emerging understanding of trafficking and antigen-specific immunity. Front Immunol. 2015;6:603. doi:https://doi.org/10.3389/fimmu.2015.00603.
- McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50(4):331–347. doi:https://doi.org/10.1016/j.plipres.2011.04.002.
- Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res. 2009;50(Suppl):S364–S369. doi:https://doi.org/10.1194/jlr.R800092-JLR200.
- Abdolreza R-M, Thomas M, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6. Atheroscler Thromb Vasc Biol. 2002;22(7):1194–1199. doi:https://doi.org/10.1161/01.ATV.0000022694.16328.CC.
- Hol J, Otterdal K, Breland UM, et al. Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS One. 2012;7(7):e40673. doi:https://doi.org/10.1371/journal.pone.0040673.
- Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev. 2017;13(3):209–216. doi:https://doi.org/10.2174/1573403X13666170426104611.
- Milajerdi A, Larijani B, Esmaillzadeh A. Statins influence biomarkers of low grade inflammation in apparently healthy people or patients with chronic diseases: a systematic review and meta-analysis of randomized clinical trials. Cytokine. 2019;123:154752. doi:https://doi.org/10.1016/j.cyto.2019.154752.
- Milajerdi A, Sadeghi A, Mousavi SM, et al. Influence of statins on circulating inflammatory cytokines in patients with abnormal glucose homeostasis: a meta-analysis of data from randomized controlled trials. Clin Ther. 2020;42(2):e13–e31. doi:https://doi.org/10.1016/j.clinthera.2019.12.009.
- Tabrizi R, Tamtaji OR, Mirhosseini N, et al. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;141:85–103. doi:https://doi.org/10.1016/j.phrs.2018.12.010.
- Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007;28(2):88–98. doi:https://doi.org/10.1016/j.it.2006.12.003.
- Zineh I, Luo X, Welder GJ, et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy. 2006;26(3):395–340. doi:https://doi.org/10.1592/phco.26.3.333.
- Dunoyer-Geindre S, Dimitrova Y, Fish RJ, et al. Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thromb Haemost. 2005;93(2):339–345. doi:https://doi.org/10.1160/TH04-05-0297.
- Bahrami A, Parsamanesh N, Atkin SL, et al. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230–238. doi:https://doi.org/10.1016/j.phrs.2018.08.014.
- Li D, Chen H, Romeo F, et al. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther. 2002;302(2):601–605. doi:https://doi.org/10.1124/jpet.102.034959.
- Omi H, Okayama N, Shimizu M, et al. Statins inhibit high glucose-mediated neutrophil–endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc Res. 2003;65(2):118–124. doi:https://doi.org/10.1016/S0026-2862(02)00033-X.
- Zapolska-Downar D, Siennicka A, Kaczmarczyk M, et al. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells . Life Sci. 2004;75(11):1287–1302. doi:https://doi.org/10.1016/j.lfs.2004.03.005.
- Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol. 2000;165(5):2712–2718. doi:https://doi.org/10.4049/jimmunol.165.5.2712.
- Schmidt A, Goepfert C, Feitsma K, Buddecke E. Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-α activated human vascular endothelial cells. Atherosclerosis. 2002;164(1):57–64. doi:https://doi.org/10.1016/S0021-9150(02)00053-9.
- Brie D, Sahebkar A, Penson PE, et al. Effects of pentoxifylline on inflammatorymarkers and blood pressure: a systematic reviewandmeta-analysis of randomized controlled trials. J Hypertens. 2016;34(12):2318–2329. doi:https://doi.org/10.1097/HJH.0000000000001086.
- Raimondo DD, Tuttolomondo A, Buttà C, Miceli S, Licata G, Pinto A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des. 2012;18(28):4385–4413. doi:https://doi.org/10.2174/138161212802481282.
- Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109(4):175–180. doi:https://doi.org/10.1016/S0049-3848(03)00064-1.
- Schiro A, Wilkinson FL, Weston R, et al. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis. 2014;234(2):295–302. doi:https://doi.org/10.1016/j.atherosclerosis.2014.03.019.
- Sinning J-M, Losch J, Walenta K, et al. Circulating CD31+/Annexin V + microparticles correlate with cardiovascular outcomes. Eur Heart J. 2011;32(16):2034–2041. doi:https://doi.org/10.1093/eurheartj/ehq478.
- Angelot F, Seillès E, Biichlé S, et al. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. Haematologica. 2009;94(11):1502–1512. doi:https://doi.org/10.3324/haematol.2009.010934.
- Wang Y, Liu J, Chen X, et al. Dysfunctional endothelial-derived microparticles promote inflammatory macrophage formation via NF-кB and IL-1β signal pathways. J Cell Mol Med. 2019;23(1):476–486. doi:https://doi.org/10.1111/jcmm.13950.
- Serban KA, Rezania S, Petrusca DN, et al. Structural and functional characterization of endothelial microparticles released by cigarette smoke. Sci Rep. 2016;6:31596. doi:https://doi.org/10.1038/srep31596.
- Arteaga RB, Chirinos JA, Soriano AO, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol. 2006;98(1):70–74. doi:https://doi.org/10.1016/j.amjcard.2006.01.054.
- Wheway J, Latham SL, Combes V, Grau GE. Endothelial microparticles interact with and support the proliferation of T cells. J Immunol. 2014;193(7):3378–3387. doi:https://doi.org/10.4049/jimmunol.1303431.
- Lu Y, Li L, Yan H, et al. Endothelial microparticles exert differential effects on functions of Th1 in patients with acute coronary syndrome. Int J Cardiol. 2013;168(6):5396–5404. doi:https://doi.org/10.1016/j.ijcard.2013.08.050.
- Fu Z, Zhou E, Wang X, et al. Oxidized low-density lipoprotein-induced microparticles promote endothelial monocyte adhesion via intercellular adhesion molecule 1. Am J Physiol Cell Physiol. 2017;313(5):C567–C574. doi:https://doi.org/10.1152/ajpcell.00158.2016.
- Tramontano AF, O'Leary J, Black AD, et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun. 2004;320(1):34–38. doi:https://doi.org/10.1016/j.bbrc.2004.05.127.
- Almquist T, Mobarrez F, Jacobson SH, et al. Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. 2016;31(6):944–952. doi:https://doi.org/10.1093/ndt/gfv337.
- Diamant M, Tushuizen ME, Abid-Hussein MN, et al. Amsterdam Cardiovascular Sciences, Other Research, Laboratory for Experimental Clinical Chemistry, Cancer Center Amsterdam, Laboratory for General Clinical Chemistry, Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost. 2008;100(09):489–497. doi:https://doi.org/10.1160/TH07-12-0760.
- Mobarrez F, Egberg N, Antovic J, et al. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res. 2012;129(1):95–97. doi:https://doi.org/10.1016/j.thromres.2011.09.027.
- Tehrani S, Mobarrez F, Lins P-E, et al. Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes. Diabetes Vasc Dis Res. 2013;10(6):483–488. doi:https://doi.org/10.1177/1479164113491275.
- Lins LCA, França CN, Fonseca FAH, et al. Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys. 2014;70(1):687–696. doi:https://doi.org/10.1007/s12013-014-9973-9.
- Wang J-M, Su C, Wang Y, et al. Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. J Hum Hypertens. 2009;23(5):307–315. doi:https://doi.org/10.1038/jhh.2008.137.
- Bulut D, Becker V, Mügge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol. 2011;89(4):239–244. doi:https://doi.org/10.1139/y11-013.
- Jufri NF, Mohamedali A, Avolio A, Baker MS. Mechanical stretch: physiological and pathological implications for human vascular endothelial cells. Vasc Cell. 2015;7:8. doi:https://doi.org/10.1186/s13221-015-0033-z.
- Loperena R, Van Beusecum JP, Itani HA, et al. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovasc Res. 2018;114(11):1547–1563. doi:https://doi.org/10.1093/cvr/cvy112.
- Kirabo A, Fontana V, de Faria APC, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642–4656. doi:https://doi.org/10.1172/JCI74084.
- Souilhol C, Harmsen MC, Evans PC, Krenning G. Endothelial-mesenchymal transition in atherosclerosis. Cardiovasc Res. 2018;114(4):565–577. doi:https://doi.org/10.1093/cvr/cvx253.
- Evrard SM, Lecce L, Michelis KC, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun. 2016;7:11853–11816. doi:https://doi.org/10.1038/ncomms11853.
- Chen P-Y, Qin L, Baeyens N, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015;125(12):4514–4528. doi:https://doi.org/10.1172/JCI82719.
- Lv Z, Wang Y, Liu Y-J, et al. NLRP3 inflammasome activation contributes to mechanical stretch-induced endothelial-mesenchymal transition and pulmonary fibrosis. Crit Care Med. 2018;46(1):e49–e58. doi:https://doi.org/10.1097/CCM.0000000000002799.
- dos Santos G, Rogel MR, Baker MA, et al. Vimentin regulates activation of the NLRP3 inflammasome. Nat Commun. 2015;6(1):5. doi:https://doi.org/10.1038/ncomms7574.
- Nieminen M, Henttinen T, Merinen M, et al. Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol. 2006;8(2):156–162. doi:https://doi.org/10.1038/ncb1355.
- Ciraci C, Janczy JR, Sutterwala FS, Cassel SL. Control of innate and adaptive immunity by the inflammasome. Microbes Infect. 2012;14(14):1263–1270. doi:https://doi.org/10.1016/j.micinf.2012.07.007.
- Helmke A, Casper J, Nordlohne J, et al. Endothelial-to-mesenchymal transition shapes the atherosclerotic plaque and modulates macrophage function. FASEB J. 2019;33(2):2278–2289. doi:https://doi.org/10.1096/fj.201801238R.
- Tsai T-H, Lee C-H, Cheng C-I, et al. Liraglutide inhibits endothelial-to-mesenchymal transition and attenuates neointima formation after endovascular injury in streptozotocin-induced diabetic mice. Cells. 2019;8(6):589. doi:https://doi.org/10.3390/cells8060589.
- Tian D, Zeng X, Wang W, et al. Protective effect of rapamycin on endothelial-to-mesenchymal transition in HUVECs through the Notch signaling pathway. Vascul Pharmacol. 2019;113:20–26. doi:https://doi.org/10.1016/j.vph.2018.10.004.
- Ma Z, Zhu L, Liu Y, et al. Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-β1 signaling. Front Pharmacol. 2017;8:473. doi:https://doi.org/10.3389/fphar.2017.00473.
- Milara J, Escrivá J, Ortiz JL, et al. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study. Eur Respir J. 2016;47(6):1737–1749. doi:https://doi.org/10.1183/13993003.01259-2015.
- Nagai T, Kanasaki M, Srivastava SP, et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed Res Int. 2014;2014:696475., (). doi:https://doi.org/10.1155/2014/696475.
- You S, Qian J, Wu G, et al. Schizandrin B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-κB activation. Phytomedicine. 2019;62:152955. doi:https://doi.org/10.1016/j.phymed.2019.152955.
- Wu Q-Q, Xiao Y, Jiang X-H, et al. Evodiamine attenuates TGF-β1-induced fibroblast activation and endothelial to mesenchymal transition. Mol Cell Biochem. 2017;430(1–2):81–90. doi:https://doi.org/10.1007/s11010-017-2956-6.
- Shi R, Zhu D, Wei Z, et al. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition. Life Sci. 2018;207:442–450. doi:https://doi.org/10.1016/j.lfs.2018.06.033.
- Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007;9:121–167. doi:https://doi.org/10.1146/annurev.bioeng.9.060906.151959.
- Yang X, Meegan JE, Jannaway M, et al. A disintegrin and metalloproteinase 15-mediated glycocalyx shedding contributes to vascular leakage during inflammation. Cardiovasc Res. 2018;114(13):1752–1763. doi:https://doi.org/10.1093/cvr/cvy167.
- Padberg J-S, Wiesinger A, di Marco GS, et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis. 2014;234(2):335–343. doi:https://doi.org/10.1016/j.atherosclerosis.2014.03.016.
- Ikonomidis I, Voumvourakis A, Makavos G, et al. Association of impaired endothelial glycocalyx with arterial stiffness, coronary microcirculatory dysfunction, and abnormal myocardial deformation in untreated hypertensives. J Clin Hypertens. 2018;20(4):672–679. doi:https://doi.org/10.1111/jch.13236.
- Nemoto T, Minami Y, Yamaoka-Tojo M, et al. Endothelial glycocalyx and severity and vulnerability of coronary plaque in patients with coronary artery disease. Atherosclerosis. 2020;302:1–7. doi:https://doi.org/10.1016/j.atherosclerosis.2020.04.014.
- McDonald KK, Cooper S, Danielzak L, Leask RL. Glycocalyx degradation induces a proinflammatory phenotype and increased leukocyte adhesion in cultured endothelial cells under flow. PLoS One. 2016;11(12):e0167576. doi:https://doi.org/10.1371/journal.pone.0167576.
- Voyvodic PL, Min D, Liu R, et al. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem. 2014;289(14):9547–9559. jbc.M113.541573. doi:https://doi.org/10.1074/jbc.M113.541573.
- Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195(1):99–111. doi:https://doi.org/10.1084/jem.20001858.
- Termeer CC, Hennies J, Voith U, et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol. 2000;165(4):1863–1870. doi:https://doi.org/10.4049/jimmunol.165.4.1863.
- Do Y, Nagarkatti PS, Nagarkatti M. Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrow-derived dendritic cells. J Immunother. 2004;27(1):1–12. doi:https://doi.org/10.1097/00002371-200401000-00001.
- Meuwese MC, Mooij HL, Nieuwdorp M, et al. Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res. 2009;50(1):148–153. doi:https://doi.org/10.1194/jlr.P800025-JLR200.
- Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(12):2646–2655. doi:https://doi.org/10.1007/s00125-010-1910-x.